应用Ig/TCR重排监测儿童淋巴瘤微小残留病

Using Ig/TCR gene rearrangements to monitor minimal residual disease in pediatric lymphoma

淋巴瘤微小残留病（MRD）的准确检测对判断预后、评价疗效、监测复发和指导治疗具有十分重要的意义.免疫球蛋白（Ig）/T细胞受体（TCR）重排可以作为肿瘤特异性PCR标志用于MRD的监测.BIOMED-2策略是欧洲协作组制定的标准化多重PCR反应方法.MRD的检测可以通过实时荧光定量PCR的方法完成.对Ig/TCR重排监测儿童淋巴瘤MRD的原理及其相关研究进展进行了综述.

Detection of minimal residual disease （MRD） exactly for lymphoma is important for estimating prognosis, assessing response, monitoring relapse and instructing treatment. Immunoglobulin （Ig）/T-cell receptor （TCR） gene rearrangements can be used as special tumorous markers for MRD testing by PCR.BIOMED-2 strategy is a method about multiplex PCR reaction designed by European Collaborative Organization. Monitoring MRD can be completed by real-time quantitative PCR. In this paper, the principle and research progress related to the application of IG/TCR in MRD detection are mainly reviewed for lymphoma in children.